# Evgen Pharma plc SFX-01 product candidate now into two phase II clinical trials

- Link: https://www.directorstalkinterviews.com/evgen-pharma-plc-sfx-01-product-candidate-now-two-phase-ii-clinical-trials/412730214
- Published: 2017-06-13T07:25:49+01:00
- Author: Giles Arbor

**Evgen Pharma plc** (LON:EVG), the clinical stage drug development company focused
on the treatment of cancer and neurological conditions, announced today its final
results for the year ended 31 March 2017.

Highlights

* First patient dosed in the ongoing SAS (SFX-01 After Subarachnoid Haemorrhage)
Phase II clinical study

* First patient dosed in the ongoing STEM (SFX-01 in the Treatment and Evaluation
of Metastatic Breast Cancer) Phase IIa clinical study

* Orphan drug designation granted by the US Food & Drug Administration for the use
of stabilised sulforaphane in subarachnoid haemorrhage (“SAH”)

* Positive data from preclinical studies of SFX-01 in various models of the relapsing
remitting form of multiple sclerosis (“MS”) presented at leading MS conference

* Additional patents granted over manufacturing processes for SFX-01

* Recently, and subsequent to the period, the first patient to enter the STEM trial
has now been accepted onto the compassionate use programme, having demonstrated 
no disease progression during the trial

* Financial performance in line with expectations:

– Total comprehensive loss of £3.1m (2016: loss of £3.1m)

– Net cash outflow (before short-term investment movements) of £3.3m (2016: inflow
of £6.9m)

– Cash and short term investments and cash on deposit at 31 March 2017 of £3.9m (
31 March 2016: £7.1m)

> **Dr Stephen Franklin, Chief Executive Officer of Evgen Pharma plc, said:** “We
> are very pleased to have progressed our SFX-01 product candidate into two phase
> II clinical trials: in breast cancer and in subarachnoid haemorrhage. This is 
> a significant step for Evgen Pharma, and for sulforaphane-based science.
> “The increasing body of evidence that sulforaphane has broad therapeutic potential,
> combined with our expanding IP portfolio over technology for manufacturing sulforaphane-
> based drugs at commercial scale, gives Evgen Pharma confidence in its clinical
> strategy.”

Share on: